High-dose chemotherapy with autologous blood stem cell support has become the most commonly used treatment in multiple myeloma (MM). Although it has greatly improved event-free and overall survival of patients, the vast majority of them relapse after a variable remission period due to persisting residual tumor cells. Molecular detection of MM tumor cells is based on the immunoglobulin heavy-chain (IgH) gene rearrangement, the sequence of which is unique to each tumor clone and is stable throughout the disease. The wide development of realtime PCR devices offers the possibility to quantify accurately the tumor cells with an allele-specific oligonucleotide (ASO) IgH PCR. The design of individual clono-specific fluorogenic probes is particularly expensive; therefore, germline consensus probe use, along with a patient specific primer, is advisable. But, in MM, the hypermutated status of IgH clonal sequences renders delicate the choice of consensus probes and primers, and is considered as a technical challenge for IgH PCR assay. We have investigated two detection strategies for MM ASO PCR on LightCycler (Roche Applied Science, Meylan, France): with a set of three consensus bi-fluorogenic probes located in the JH region and/or with the DNA intercalating dye SYBR Green I (see supplemental Figure 1 ). Moreover, we developed a new relative quantification method taking advantage of the 'RelQuant' software (Roche Applied Science) with external standards and an internal calibrator sample. In order to evaluate the relevance of our assay in the clinical setting, ASO IgH real-time quantitative (RQ) PCR was applied to determine the tumor load in leukapheresis products, postautograft bone marrow (BM) and peripheral blood (PB) samples from MM patients.
First, IgH consensus PCR was performed under previously described conditions, 1 for 10 MM patients and a lymphoblastoid cell line. Monoclonal purified IgH consensus PCR products were directly sequenced following Applied Biosystems (Courtaboeuf, France) recommendations. The ASO primer was derived from the hypervariable complementary determining region CDR3 (N-D-N). Then, quantitative IgH PCR was performed between the ASO CDR3 primer and a consensus primer located in either JH or VH region, with QuantiTect PCR Probe kit or QuantiTect PCR SYBR Green kit (Qiagen, Courtaboeuf, France). Fluorescent PCR product accumulation was monitored by the LightCycler using either SYBR Green I dye or germline fluorogenic hydrolysis probes located in the JH region, as previously developed by Verhagen et al 2 in acute lymphoblastic leukemia. All PCR reactions were run with a maximum of 200 ng DNA for SYBR Green or 500 ng DNA for hydrolysis probe in duplicate glass capillaries. The DNA input was normalized using reference gene quantification. The BM from diagnosis was considered as the calibrator sample for which the tumor load was set to 1, and all samples were referred to it. The PCR efficiency was measured for each ASO IgH RQ PCR by eight-fold serial dilution of tumor clone DNA in pooled DNA obtained from four normal PB volunteers. For technical details, see supplementary information.
ASO IgH RQ PCR was optimized on a lymphoma cell line and on one patient's tumor cells for fluorogenic probe and SYBR Green I techniques. Both methods led to the successful amplification and detection of the clonal rearrangements with an adequate specificity (see supplemental Table 1 ). For the cell line, the maximum sensitivity reached 3E-05 corresponding to one cell (one copy of target sequence) detected in the DNA from around 30 000 cells tested, validating the use of either hydrolysis probe or SYBR Green I approach. However, linearity only ranged a dilution from 1 to 2.44E-04 corresponding to eight cells (supplemental Table 2 ). As previously described for IgH PCR, 3 the amplification of a small amount of initial target gene resulted in statistical heterogeneity preventing precise quantification.
Among the 10 patients included in this study, three ASO PCR were performed with only hydrolysis probe, six with only SYBR Green I, and one with both detection methods (see supplemental Table 1 ). The intronic JH primers used for the hydrolysis probe approach did not match the tumor rearrangement in four cases. Somatic hypermutations, affecting the intron sequence located in 5 0 from JH segments, 4 may cause such an amplification failure. The appropriate JH consensus hydrolysis probe could hybridize the four ASO PCR performed with this strategy.
Specificity tests using samples unrelated to the patients were successful for all ASO IgH RQ PCR. Efficiency tests were better with hydrolysis probe than SYBR Green I in our series (see supplemental information and Table 2 ).
Theoritical sensitivity was increased with hydrolysis probe strategy since it was possible to introduce up to 500 ng DNA in the 20 ml PCR reactions. The initial amount of DNA could not exceed 200 ng for SYBR Green I strategy because larger amounts of DNA resulted in fluorescence emission masking the neosynthesized PCR products. In conclusion of this validation step, both approaches were complementary since the SYBR Green I detection approach, even with a lesser sensitivity, increased the number of effective ASO IgH quantitative PCR in our MM patients.
The originality of our approach leans on the RQ PCR results analysis method. In order to take into account the quantity and the quality of starting materials, results were normalized by a reference gene. Concerning the calibration curve, the use of plasmid standards or dilution of purified PCR products was rejected because it did not correspond to the patients' sample conditions with regard to conformation and accessibility of DNA polymerase with the target. Therefore, the initial BM sample taken at diagnosis was preferred but the absolute number of tumor cells was difficult to ascertain in this sample since MM BM tumor involvement is considered to be very heterogeneous. Thus, we chose a relative quantitative assay with the BM DNA at diagnosis that constituted our calibrator sample included in all PCRs.
A rapid and convenient software named RelQuant (Roche Applied Science) was used to calculate results relative to the initial BM. The RelQuant software was chosen because it takes into account the efficiency of ASO and reference gene PCRs, determined once by an external standard curve. Since RelQuant software was only adequate when the same PCR efficiency could be guaranteed for each different run, the reproducibility of ASO PCR efficiency was tested (see supplemental Table 3 ). With an efficiency variation of 4%, our assay corresponds to the manufacturer's recommendations, but such a variation asks for caution on interpretation of low differences in tumor load.
Results with this software were compared with the conventional data analysis methods: (i) the comparative cycle threshold (Ct) method (see supplemental Table 4 ), (ii) the absolute quantification with internal standard (see supplemental Table  5 ). For the comparative Ct method, equivalent efficiencies between target gene and reference gene PCRs were required. In this study, only three ASO PCR among the patients' specific IgH PCR designed satisfied this condition (see supplemental Table 6 ) and gave similar results to the RelQuant software. The results with the absolute quantification with internal standard method were also equivalent to the RelQuant software.
A major advantage of the RelQuant software was the PCR efficiency determination for each crossing point (Cp) value, based on a mathematical algorithm previously reported and discussed. 5 Therefore, theoretical accuracy of results was increased compared to more classical relative quantification with linear standard efficiency determination. In our application, Relquant software allowed an easy and convenient calculation of the tumor cell ratio with a PCR efficiency correction and an inter-PCR variation normalization.
Our technique of tumor cell quantification was applied to the following clinical MM samples: PB obtained during the diagnosis procedure; PBSC harvests; BM and PB after autologous transplantation (Figure 1) . MM is mainly characterized by the accumulation of clonal cells in the BM, but presence of related malignant cells in the peripheral circulation has also been detected by ASO IgH RQ PCR at diagnosis for eight out of our 10 patients. The tumor load was approximately 2 log inferior to that of BM and varied between 8.12E-04 and 1.42E-02. The clinical significance of these circulating cells is still controversial since it has been hypothesized that circulating cells may spread the disease. 6 Between one and four leukaphereses were collected from nine patients depending on the CD34 þ cell content in the PBSC products. For patient #03, however, mobilization treatment failed and PBSC could not be harvested. The leukapheresis contamination measured by ASO IgH RQ PCR varied between 1.19E-03 and 1.92E-02 for six patients whereas the tumor rearrangement was not detected in PBSC for the three other patients. As previously described, 7 only small variations could be observed between each leukapheresis during the same mobilization course. For five patients out of 10, the tumor contamination was higher in PBSC than in PB MNC at diagnosis. This could indicate that mobilization treatment is able to promote the entrance of tumor cells into the peripheral circulation.
ASO IgH PCR is particularly adequate for the MM tumor cell follow-up during therapy since myeloma IgH sequence is stable and does not undergo further hypermutation during the disease. In our study, molecular remission was reached in two out of nine patients (patients #08 and #10) with a short median time of follow-up. For five other patients (#01,#04,#05,#06,#07), the tumor load was stable (around 10 À1 and 10 À3 ) for 180 days up to 1 year after graft. For one of these patients (#01), a dramatic increase of the BM tumor load occurred 540 days after graft and 3 months before the clinical relapse. For patients #02 and #09, there was a constant increase in the BM tumor load, which preceded their relapse. In line with Fenk et al., 8 we noticed the relapse or the increase in tumor load in the BM to be concomitant with the reappraisal of tumor cells detectable in the peripheral circulation and we also confirmed in our series that the increase of the tumor load in BM preceded or accompanied the clinical relapse. However, our observations need to be confirmed with a larger series of patients.
Overall, ASO IgH RQ PCR using either germline fluorogenic probes or SYBR Green as detection system was feasible with the LightCycler. The relative quantitative analysis using the BM sample, taken at diagnosis as calibrator, normalized with a reference gene and with the help of Relquant software to correct PCR efficiency, proved to be of interest to obtain rapid and accurate results of MRD quantification in MM disease. Our results may indicate the predictive value of the molecular follow-up in the clinical setting. BM tumor load at diagnosis was set to 1 and all patient's samples were referred to this calibrator sample (except for patient #09 for which relapse sample was considered as the calibrator). The tumor load is represented by bars on BM samples, dots on PB samples, diamond shapes on PBSC samples. When PB samples are below the detection limit, they are represented by triangles, whereas concomitant ASO PCR negativity in BM and PB is shown as squares. In order to clarify the figure for the PBSC and blood samples, only standard deviations 4 to 20% are represented. The SYBR Green I approach was used for patients #01,02,03,04,07 and 09, whereas the hydrolysis approach was performed for patients #05,06,08 and 10. Tumor cell quantification and clinical status evaluation were performed at different time length after transplantation. CR indicates complete remission; PR, partial remission; Rel., relapse; diag., diagnosis; D, deceased; DU, deceased from unrelated problem.
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